Uptake of Controlled Release Drug Delivery Technology Set to Increase?
News Dec 11, 2017 | Future Market Insights (FMI)
Oral Controlled Release Drug Delivery Technology Reports Increased Uptake, Observes Future Market Insights
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages. Moreover, the uptake of controlled release drug delivery technology is anticipated to increase further in the near future with a large pool of drug manufacturers setting up their production unit across various regions, especially in Brazil, Costa Rica, Argentina, and Mexico.
Since the combination of several technologies assists in conquering the issues associated with poorly soluble candidates rapidly, the adoption of this technique is also increasing significantly. Being supported through increased sharing of technologies using various symposiums and conferences, where enterprises that share similar thought processes come together and plan eventual outcomes, which significantly helps in providing better pricing and swift time to market for the otherwise unfeasible products in the lesser period of time. An increased adoption of combination approaches is anticipated to propel the worldwide market for oral controlled release drug delivery technology in the years to come.
Over the next few years, the rising number of approvals of modified oral drugs by PMDA is likely to boost the revenue from oral controlled release drug delivery technology in Japan. In case of new approvals, a preference for capsules and tablets can be observed across the world, since formulation researchers find it easier to create formulations for therapeutic as well as clinical purposes.
Controlled Release Formulations – A common strategy to extend the product life cycle
Controlled Release is the most common strategy adopted by Pharma giants across the globe to extend the product life cycle. Modified or controlled release formulations of pre-approved drugs are enjoying extended market exclusivity. The introduction of proprietary prescribed medicines in controlled release forms will help drive revenue growth of the global market. Other release mechanisms include enteric release, osmotically active release, effervescent and sublingual release. OROS (Johnson & Johnson and Alza Corporation) and SODAS (Elan Technologies) are the most commercialised technologies in the oral controlled release drug delivery technology market.
This article has been republished from materials provided by Future Market Insights (FMI). Note: material may have been edited for length and content. For further information, please contact the cited source.
Research Report available here.
Fragile X: Drug Strategy Could Alleviate Behavioral & Cellular DeficienciesNews
Research in mice shows that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome (FXS), the most common inherited form of intellectual disability and a major single-gene cause of autism spectrum disorders.READ MORE
Availability of Brain Tumor Surgery Dye Increases for NHS PatientsNews
A chemical dye that lights up brain tumours during surgery should be available to more NHS patients in England, according to the National Institute for Health and Care and Excellence (NICE).READ MORE